For any B2B player sourcing peptides into the U.S. market, the regulatory picture in 2025–2026 is the most restrictive it has been in years — and the single biggest source of supply risk. The story splits into two lanes that are easy to conflate: (1) GLP-1 agonists and (2) the broader "research/wellness" peptide class.
Lane 1 — GLP-1s. During the 2023–2024 shortages, compounded semaglutide and tirzepatide were widely available because federal law permits compounding copies of drugs in shortage. Those shortages resolved (tirzepatide Oct 2024, semaglutide Feb 2025), and the FDA's enforcement-discretion windows closed through May 2025. Following shortage resolution, routine copies generally face tighter restrictions; permissibility depends on the applicable 503A or 503B conditions and documented patient-specific circumstances. In April 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list entirely. A September 2026 warning letter to Empower Pharmacy (Houston) illustrated the agency's enforcement position in that matter: adding B12 or niacinamide does not make a compounded GLP-1 "not essentially a copy," and high production volume suggests differences are "pretextual."
Lane 2 — the wellness/research peptide class. The FDA uses a three-category bulks system: Category 1 (may be compounded), Category 2 (significant safety concerns — do not compound), and Category 3 (insufficient data). In September 2023 the FDA placed 19 peptides — including BPC-157, TB-500, ipamorelin and melanotan II — in Category 2. In April 2026 it removed 12 of those (including BPC-157, TB-500, GHK-Cu, KPV, MOTS-c, semax, epitalon) after nominations were withdrawn — but removal from Category 2 does not by itself establish eligibility for compounding under section 503A. At the July 2026 PCAC meeting, the committee voted to recommend adding six peptides (BPC-157, KPV, TB-500, semax, MOTS-c, epitalon) to the 503A bulks list for narrow indications, with several close votes and the FDA's own scientists recommending against all of them. As of late 2026, a favorable advisory discussion would not itself authorize compounding; final eligibility depends on FDA action and the statutory conditions applicable to the specific preparation.
Congress is reinforcing the trend. If enacted, the SAFE Drugs Act of 2025 (H.R. 6509) would redefine "essentially a copy," cap 503A pharmacies at 20 copies/month of any single drug, mandate reporting for out-of-state shippers, and remove the $15,000 establishment-fee cap for 503B facilities. At publication it remains proposed legislation, so its provisions should be treated as a policy signal rather than current law.
B2B implication: sourcing risk now lives in the grey market. "Research use only" labels do not shield sellers whose marketing implies human use, and a 2024 market-surveillance study found products labelled 99% purity actually measured 7.7%–14.4% — and three of six orders never arrived. Buy from suppliers who can show GMP/quality documentation, transparent CoA, and a clear regulatory position for the specific molecule and route.
B2B buyer takeaways
- After shortage resolution, routine copies of semaglutide or tirzepatide generally face tighter U.S. restrictions; eligibility depends on the applicable statutory conditions and patient-specific facts.
- Removal from Category 2 does not by itself establish eligibility to compound.
- PCAC votes are advisory; final rulemaking may take until 2027.
- If enacted, the SAFE Drugs Act would tighten copy definitions, volume caps and 503B fees; monitor its legislative status.
- Demand for compliant, documented supply is rising; qualify suppliers on GMP evidence, not price or claims.
Sources & References
1. Peptide Journal, "FDA Peptide Regulation: Complete 2025-2026 Timeline" https://www.peptidejournal.org/legal/fda-peptide-regulation-complete-2025-2026-timeline
2. Vial Audit, "503A, the PCAC and GLP-1 compounding: Oct 2026 status" https://vialaudit.com/articles/503a-pcac-glp1-compounding
3. Peptide Basics, "FDA Peptide Update 2026: July PCAC Meeting" https://www.peptidebasics.com/fda-peptide-update-2026
4. Nexsis BioHealth, "Peptide Therapy Miami: What to Know" (grey-market risks, JMIR study) https://nexsisbiohealth.com/blog-posts/peptide-therapy-miami-what-to-know-before-your-consultation
5. Peptide Laws, "FDA Peptide Regulations 2026" https://peptidelaws.com/news/fda-peptide-regulations-2026
Editorial summary of third-party reporting only; not legal, medical, investment or regulatory advice. Figures, market estimates and regulatory statements reflect the cited source and publication date, and should be rechecked for the relevant product, jurisdiction and intended use.